Tocilizumab Injection
Tocilizumab injection is a prescription biologic that treats inflammatory conditions including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, systemic sclerosis-associated interstitial lung disease, cytokine release syndrome, and severe COVID-19.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 5 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Tocilizumab carries a serious FDA boxed warning about the risk of life-threatening infections. People taking tocilizumab are at increased risk for severe infections — including tuberculosis (TB), bacterial infections, invasive fungal infections, and viral infections — that can require hospitalization or cause death. This risk is greatest in people also taking other immune-suppressing drugs. If you develop a serious infection, treatment must be stopped until it is controlled. Before starting (except for COVID-19), you must be tested for latent (hidden) TB; if the test is positive, TB treatment should begin before tocilizumab. Even if your TB test is negative, watch for TB symptoms throughout treatment — persistent cough, night sweats, and unexplained weight loss. Report any signs of infection to your doctor right away.
📖 Tocilizumab Injection: Patient Information Guide
A plain-language walkthrough of Tocilizumab Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Tocilizumab injection is a biologic medication approved for several inflammatory, autoimmune, and immune-related conditions across multiple products and routes.
- Rheumatoid arthritis (RA): Actemra (IV or subcutaneous) treats moderate to severe RA in adults who haven't responded adequately to other disease-modifying drugs (DMARDs)
- Giant cell arteritis (GCA): Actemra (IV or subcutaneous) treats this blood vessel inflammation in adults, often alongside a steroid taper
- Systemic sclerosis-associated interstitial lung disease (SSc-ILD): Actemra subcutaneous injection slows the rate of lung function decline in adults — IV is not approved for this use
- Polyarticular juvenile idiopathic arthritis (PJIA): Actemra (IV or subcutaneous) treats active PJIA in patients 2 years and older
- Systemic juvenile idiopathic arthritis (SJIA): Actemra (IV or subcutaneous) treats active SJIA in patients 2 years and older
- Cytokine release syndrome (CRS): Actemra intravenous infusion treats severe or life-threatening CRS caused by CAR T-cell therapy in adults and children 2 and older
- COVID-19: Actemra intravenous infusion treats hospitalized adults and children 2 and older with COVID-19 who are on systemic corticosteroids and need supplemental oxygen, mechanical ventilation, or ECMO
⚙️How it works▾
Tocilizumab is an IL-6 receptor antagonist — it blocks a pro-inflammatory signaling protein called interleukin-6 (IL-6). IL-6 is released by immune cells and drives inflammation throughout the body, activating immune cells, triggering liver proteins that fuel inflammation, and causing joint damage in diseases like rheumatoid arthritis. Tocilizumab attaches to both the free and cell-surface forms of the IL-6 receptor, preventing IL-6 from delivering its inflammatory signal and helping bring the immune response back under control.
💊How it's taken▾
Tocilizumab injection is given either by slow intravenous (IV) infusion over one hour in a clinical setting, or as a subcutaneous (under-the-skin) injection at home — the route and frequency depend on your specific condition. IV infusions are typically scheduled every 2 to 4 weeks depending on the indication; subcutaneous injections are given weekly or every other week. There are no food-related restrictions.
- Do not change your dose schedule based on a single body weight reading — weight can fluctuate
- If a dose adjustment or interruption is needed (for example, due to lab changes), your prescriber will guide you — do not adjust on your own
- Always follow the Instructions for Use included with your specific product and device
🤒Side effects — in detail▾
The most commonly reported side effects with tocilizumab injection include:
- Upper respiratory tract infections and nasopharyngitis (cold-like symptoms)
- Headache
- High blood pressure (hypertension)
- Elevated liver enzymes (ALT) on blood tests
- Injection site reactions (redness, pain, or swelling at the injection site)
- Low white blood cell counts (neutropenia) — detected on blood tests
- Low platelet counts (thrombocytopenia) — detected on blood tests
- Increased cholesterol and triglyceride levels
Serious reactions to act on immediately include signs of infection (fever, chills, cough), severe stomach pain that could indicate intestinal perforation, signs of liver injury (jaundice, dark urine, fatigue), and any severe allergic reaction such as trouble breathing or throat tightening.
⚠️Warnings & precautions▾
- Serious infections: Tocilizumab suppresses the immune system and substantially raises the risk of dangerous infections — including tuberculosis, bacterial pneumonia, fungal infections, herpes zoster, and sepsis. Do not start treatment during any active infection. Get tested for latent TB before starting (except COVID-19 patients).
- Liver injury (hepatotoxicity): Serious liver damage, including cases requiring liver transplant or death, has been reported. Liver enzyme levels must be checked before and regularly during treatment. Stop the medication and contact your doctor if you develop jaundice, fatigue, or right-sided abdominal pain.
- Gastrointestinal perforation: Holes in the intestine (perforations) have occurred, particularly in people with a history of diverticulitis. Seek immediate care for sudden severe abdominal pain with fever.
- Blood count and lipid changes: Tocilizumab can lower white blood cells and platelets and raise cholesterol — regular monitoring with blood tests is required.
- Severe allergic reactions: Anaphylaxis and fatal hypersensitivity reactions have occurred; a serious skin reaction called DRESS has also been reported. Infusions must be given in a setting where these can be treated immediately.
- Malignancy risk: The long-term effect on cancer risk is not fully known; malignancies have been observed in clinical studies.
- Live vaccines: Must be avoided during treatment — they may cause serious infection in people on immunosuppressive therapy.
🔀What it interacts with▾
Tocilizumab can interact with several types of medications — tell your prescriber and pharmacist about everything you take:
- Live vaccines: Must not be given during tocilizumab treatment — risk of serious infection
- CYP450-metabolized drugs (warfarin, cyclosporine, theophylline, oral contraceptives, lovastatin, atorvastatin, omeprazole, simvastatin, and others): Tocilizumab changes how the liver processes these drugs, potentially lowering their levels in your blood — doses may need monitoring and adjustment; this effect can last for weeks after stopping tocilizumab
- Other biologic DMARDs (TNF blockers, IL-1 blockers, anti-CD20 drugs, co-stimulation modulators): Combining these with tocilizumab is not recommended due to a greatly increased risk of serious infections and immune suppression
- Methotrexate and corticosteroids: Commonly used with tocilizumab, but they can increase liver enzyme elevations and infection risk — monitoring is required
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Active infection: Tocilizumab must not be started if you have any active infection, including localized ones
- Tuberculosis history or exposure: You must be screened for latent TB before starting (COVID-19 patients excluded); positive results require treatment before beginning tocilizumab
- Chronic or recurrent infections: Discuss your full infection history with your doctor — the risks and benefits must be carefully weighed
- Diverticulitis or bowel problems: Risk of intestinal perforation is higher; use with caution
- Liver disease or elevated liver enzymes: Not recommended if liver enzymes are significantly elevated at baseline; regular monitoring required
- Low blood counts: Not recommended if white blood cell or platelet counts are below defined thresholds at the start of treatment
- Pregnancy: Animal studies suggest possible fetal harm; monoclonal antibodies cross the placenta in the third trimester and may affect the baby's immune system — discuss risks and benefits with your doctor before becoming pregnant
- Breastfeeding: It is not known whether tocilizumab passes into breast milk; weigh the benefits of breastfeeding against the potential risk with your doctor
- Children under 2: Safety and effectiveness have not been fully established for most uses in this age group
- Older adults (65+): Higher rate of serious infections compared to younger patients — closer monitoring is warranted
- Known allergy to tocilizumab products: Tocilizumab is contraindicated if you have had a serious allergic reaction to it before
🚑If you take too much▾
Limited information is available on tocilizumab overdose. In one reported case, a patient accidentally received a very high IV dose with no adverse effects observed; in a healthy volunteer study, the highest doses caused temporary low white blood cell counts (neutropenia). If you or someone else may have received too much, seek medical attention — the recommended approach is monitoring for signs and symptoms and treating any reactions that develop.
📡Pharmacodynamics — effects in the body▾
After dosing, tocilizumab produces measurable drops in markers of inflammation — including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor, and fibrinogen — within about 2 weeks of starting treatment. Hemoglobin levels tend to rise. White blood cell (neutrophil) counts typically fall to their lowest point within 3–5 days after a dose, then recover gradually. Cholesterol and triglyceride levels increase during treatment and require monitoring. These measurable changes reflect the drug's effect on the IL-6 pathway, though how closely they correlate with clinical benefit varies.
🔬Pharmacokinetics — how your body processes it▾
Tocilizumab is eliminated from the body through a combination of two processes — a steady linear pathway and a saturable pathway (Michaelis-Menten elimination) — meaning higher doses lead to disproportionately greater drug exposure. The drug's half-life (how long it takes for half to leave the body) varies depending on concentration but can be up to about 21.5 days at high levels. Body weight significantly affects how the drug behaves, particularly with IV dosing. The drug's effect on liver enzyme activity (CYP450) can persist for several weeks after the last dose, meaning interactions with other medications may continue even after stopping tocilizumab.
📦How to store it▾
refrigerated at 36°F to 46°F (2ºC to 8ºC). Do not freeze. in the original carton until time of use, and keep syringes and autoinjectors dry.
📄 Written from Tocilizumab Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Tocilizumab Injection
89 supplements and herbal products have documented interactions with Tocilizumab Injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 85
- Minor · 1
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Tocilizumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What conditions is this medication used for? ▾
Is it true this can make me more likely to get sick? What should I watch for? ▾
Do I need blood tests while I'm on this? What are they checking for? ▾
Can I get vaccines while I'm on tocilizumab? ▾
I take other medications. Will this interfere with them? ▾
Is it safe to take this if I'm pregnant or trying to become pregnant? ▾
Is Tocilizumab Injection available over the counter? ▾
When was Tocilizumab Injection first available? ▾
Who makes Tocilizumab Injection? ▾
💬 Answers drafted from Tocilizumab Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Tocilizumab Injection comes
Tocilizumab Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Actemra intravenous infusion is approved for rheumatoid arthritis, giant cell arteritis, polyarticular and systemic juvenile idiopathic arthritis (ages 2+), cytokine release syndrome (ages 2+), and hospitalized COVID-19 (ages 2+)
- Actemra subcutaneous injection is approved for rheumatoid arthritis, giant cell arteritis, SSc-ILD (systemic sclerosis-associated interstitial lung disease), and polyarticular and systemic juvenile idiopathic arthritis (ages 2+)
- Actemra intravenous use is not approved for SSc-ILD; intravenous administration is approved for CRS and COVID-19 but subcutaneous is not
- Tocilizumab-anoh is approved for the same indications as Actemra; always follow the specific product labeling provided with your prescription
- Actemra intravenous doses are given as a single slow drip infusion over 1 hour — never as a rapid push or bolus; it must be administered by a healthcare professional
- Actemra subcutaneous doses are injected under the skin using a prefilled syringe or, where studied, the prefilled Actemra ACTPen autoinjector — follow the Instructions for Use provided with your device
- Actemra subcutaneous administration with the prefilled ACTPen autoinjector has not been studied for SSc-ILD — the prefilled syringe should be used for that indication
- When switching from Actemra intravenous to subcutaneous dosing, give the first subcutaneous dose in place of the next scheduled IV dose — do not double up
📊 Tocilizumab Injection across the U.S. market
How Tocilizumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Tocilizumab Injection is used
A general measure of how commonly Tocilizumab Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Tocilizumab Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Tocilizumab Injection prescribed? Of the 1,596 medications we measure, Tocilizumab Injection ranks #657 by Medicaid prescriptions — more than 59% of them.
Utilization by Tocilizumab Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
0.9 ML tocilizumab 180 MG/ML Auto-Injector Most dispensed
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2106073
20 ML tocilizumab 20 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1657981
4 ML tocilizumab 20 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1657974
0.9 ML tocilizumab 180 MG/ML Prefilled Syringe
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1441527
10 ML tocilizumab 20 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1657979
0.9 ML tocilizumab-aazg 180 MG/ML Auto-Injector
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2686045
0.9 ML tocilizumab-aazg 180 MG/ML Prefilled Syringe
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2686053
4 ML tocilizumab-aazg 20 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2679431
20 ML tocilizumab-aazg 20 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2679442
10 ML tocilizumab-aazg 20 MG/ML Injection
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2679440
4 ML tocilizumab-bavi 20 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2680298
20 ML tocilizumab-bavi 20 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2680296
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Tocilizumab Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 13 of 18 listed Tocilizumab Injection NDCs with Medicaid activity.
🔍 Compare Tocilizumab Injection products
A representative set of FDA-listed product records for Tocilizumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 20 mg/mL | Intravenous | Biogen MA Inc × 3 listings | BLA | View NDC → |
| 80 mg/4 mL | Intravenous | CELLTRION USA, Inc. × 5 listings | BLA | View NDC → |
| 162 mg/0.9 mL | Intravenous | CELLTRION USA, Inc. × 2 listings | BLA | View NDC → |
| 162 mg/0.9 mL | Subcutaneous | CELLTRION USA, Inc. × 2 listings | BLA | View NDC → |
| 200 mg/10 mL | Intravenous | CELLTRION USA, Inc. × 5 listings | BLA | View NDC → |
| 400 mg/20 mL | Intravenous | CELLTRION USA, Inc. × 5 listings | BLA | View NDC → |
| 80 mg/4 mL | — | Chugai Pharmaceutical Co., Ltd. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 162 mg/0.9 mL | — | Chugai Pharmaceutical Co., Ltd. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 200 mg/10 mL | — | Chugai Pharmaceutical Co., Ltd. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 400 mg/20 mL | — | Chugai Pharmaceutical Co., Ltd. | DRUG FOR FURTHER PROCESSING | View NDC → |
| 20 mg/mL | Intravenous | Genentech, Inc. × 3 listings | BLA | View NDC → |
| 80 mg/4 mL | Intravenous | Genentech, Inc. × 2 listings | BLA | View NDC → |
| 162 mg/0.9 mL | Subcutaneous | Genentech, Inc. × 4 listings | BLA | View NDC → |
| 180 mg/mL | Subcutaneous | Genentech, Inc. × 2 listings | BLA | View NDC → |
| 200 mg/10 mL | Intravenous | Genentech, Inc. × 2 listings | BLA | View NDC → |
| 400 mg/20 mL | Intravenous | Genentech, Inc. × 2 listings | BLA | View NDC → |
| 80 mg/4 mL | Intravenous | Organon LLC | BLA | View NDC → |
| 200 mg/10 mL | Intravenous | Organon LLC | BLA | View NDC → |
| 400 mg/20 mL | Intravenous | Organon LLC | BLA | View NDC → |
Showing 44 of 44 products — FDA National Drug Code Directory. See every product, package size and price: browse all 44 Tocilizumab Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Tocilizumab Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Tocilizumab Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Tocilizumab Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 612865 3 dose forms · 18 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2106072In current FDA listingsClinical drug / strength (SCD) 0.9 ML tocilizumab 180 MG/MLRxCUI 21060730.9 ML tocilizumab-aazg 180 MG/MLRxCUI 26860450.9 ML tocilizumab-anoh 180 MG/MLRxCUI 2705435 -
Dose form (SCDF) Injection RxCUI 1657973In current FDA listingsClinical drug / strength (SCD) 4 ML tocilizumab 20 MG/MLRxCUI 16579744 ML tocilizumab-aazg 20 MG/MLRxCUI 26794314 ML tocilizumab-anoh 20 MG/MLRxCUI 27054524 ML tocilizumab-bavi 20 MG/MLRxCUI 268029810 ML tocilizumab 20 MG/MLRxCUI 165797910 ML tocilizumab-aazg 20 MG/MLRxCUI 267944010 ML tocilizumab-anoh 20 MG/MLRxCUI 270544310 ML tocilizumab-bavi 20 MG/MLRxCUI 268028720 ML tocilizumab 20 MG/MLRxCUI 165798120 ML tocilizumab-aazg 20 MG/MLRxCUI 267944220 ML tocilizumab-anoh 20 MG/MLRxCUI 270545020 ML tocilizumab-bavi 20 MG/MLRxCUI 2680296 -
Dose form (SCDF) Prefilled Syringe RxCUI 1441526No current FDA listingClinical drug / strength (SCD) 0.9 ML tocilizumab 180 MG/MLRxCUI 14415270.9 ML tocilizumab-aazg 180 MG/MLRxCUI 26860530.9 ML tocilizumab-anoh 180 MG/MLRxCUI 2705425
Look up RxCUI 612865 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Tocilizumab Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 5 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. CELLTRION USA, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.